Abstract 340P
Background
SCLC is a rapidly growing aggressive cancer that is mostly diagnosed in stage III-IV and has a poor prognosis. Sometimes it can be diagnosed in early stages. The disease course in such cases may be different.
Methods
A retrospective analysis of pts treated at Minsk City Clinical Oncology Centre and N. N. Alexandrov National Cancer Centre in 2012–2021 was performed. Cases were selected through automated search in Belarusian cancer registry using the terms “code of diagnosis: C34” and “stage: I–II” and “code of histology: 8041/3 or 8246/3.” All retrieved records were manually analyzed.
Results
A total of 173 cases were found (38.9% of all pts). 163 (94.2%) were men, mean age 63 years. Right lung was affected in 50.9% pts, upper lobe in 49.1%. Peripheral tumors were most prevalent (60.1%). Stage I was diagnosed in 46.8%. Radical surgery was performed in 68.8% pts (pneumonectomy 18, (bi)lobectomy 93, atypical resection or segmentectomy 7). Chemotherapy was used in 130 (75.1%) pts, radiotherapy to primary site in 21 (12.1%), prophylactic cranial irradiation (PCI) in only 25.4% pts. 65 (37.6%) pts experienced disease progression with median time to progression of 12.0 months (mo). 61.3% pts were disease-free at 12 mo and 38.7% at 24 mo. Metastases (Mts) were seen mostly in lymph nodes (19.7%), brain (15.6%, of which 5 (18.5%) after PCI), lungs (14.5%), liver (10.4%). Median OS was 25 mo, though in progressive cases only 20 vs. 59 mo in those without progression (plog-rank
Conclusions
SCLC is rarely diagnosed in stage I-II, but more than a third of pts stay disease-free for more than 2 years after radical treatment. Median OS was more than 2 years, influenced by stage and PCI, highlighting that early treatment may give good results. Understanding of biologic mechanisms underlying such disease course may help to understand better early events in SCLC carcinogenesis.
Legal entity responsible for the study
M. Puchinskaya.
Funding
Has not received any funding.
Disclosure
M. Puchinskaya: Financial Interests, Personal, Invited Speaker: Roche. All other authors have declared no conflicts of interest.